VERU
Veru Inc
2 reports on Veru Inc (VERU) by White Diamond Research, summarized: the thesis, evidence and key numbers. Latest: Jul 26, 2022.
No spam. Unsubscribe anytime.
VERU
2 of 2 reports
VERU
—
—
VERU Veru Inc
Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely
White Diamond Research exposes critical flaws in Veru's COVID-19 drug trial, revealing data integrity issues, methodological problems, and potential FDA rejection risks for sabizabulin treatment
VERU
—
—
VERU Veru Inc
Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely
Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment